Category: Uncategorized

AIBILI is proud to perform a study on the effectiveness of educational materials available for Vabysmo®, Eylea® and Lucentis®.

The MARVEL Study, supported by INFARMED, I.P., is conducted by the Coimbra Regional Pharmacovigilance Unit of AIBILI and aims to evaluate the effectiveness of educational materials for healthcare professionals and the target general population, as additional measures of risk minimization for the drugs Vabysmo® (faricimab), Eylea® (aflibercept) and Lucentis® (ranibizumab).

More information: https://www.infarmed.pt/web/infarmed/infarmed/-/journal_content/56/15786/9521902

Presentations:

• Abnormal retinal fluid in eyes with diabetic center-involved macular edema

Prof. José Cunha-Vaz

 

• A Conversion Model for OCTA Vessel Density Metrics in Diabetic Eyes: Angiovue vs Cirrus Angioplex

Doutora Ana Rita Santos

 

• Statins and genetics in the risk of progression of age-related macular degeneration – The Coimbra Eye Study

Dra. Patrícia Barreto

 

• Combination of Ultra-widefield Colour Fundus Photography and Optical Coherence Tomography Angiography identify different subtypes of non-proliferative diabetic retinopathy

Dra. Ana Almeida

 

Posters:

• CLARUS (or Wide-Field Fundus Imaging) Improves ETDRS Grading with Classic 7-fields Fundus Photographs

Dra. Marta Lopes

 

Audio narrated free paper:

• Statin intake time and risk for progression of age-related macular degeneration – a comparison of two Cox regression models applied to the Coimbra Eye Study

Doutora Rita Coimbra

AIBILI will be presenting at EVOLVE – Digital Transformation Summit 2023 the EVICR.net Eye Platform. This summit will be organised by APDC on October 11, 2023, in Lisbon, Portugal. The EVICR.net Eye Platform is a long-term initiative to collect longitudinal anonymised clinical data and eye images from the network’s centers across Europe. The data platform will be available for analysis by all EVICR.net partners to develop a better understanding of the progression of eye diseases and new ways to improve patient care and prevent vision loss.
Boehringer Ingelheim is funding the EVICR.net Eye Platform and a pilot study that is collecting and will analyze data in patients with intermediate AMD or early atrophic AMD.
Learn more at: https://www.evicr.net/eyeplatform/

AIBILI was present at this ERA4Health workshop – Analysis of bottlenecks and challenges in designing and conducting investigator-initiated multinational clinical studies – through Dr. Cecília Martinho and Dr. Joana Tavares, which took place in Paris, France, on 15-16/09/2023. Challenges in designing and conducting investigator-initiated multinational clinical studies were discussed.

‘À Mesa com Saúde’ is a health literacy initiative organized by Faculty of Medicine of the Coimbra University and iCBR – Coimbra Institute for Clinical and Biomedical Research, in partnership with the Coimbra School of Tourism and the Coimbra University Hospital, which consists of organizing dinners commented by chefs, scientists and clinicians, which aim to address diseases and their prevention through diet. The dinner on May 5th has Vision Sciences as its theme and has the participation of Dr. Patricia Barreto from AIBILI.

AIBILI, as Coordinating Centre of EVICR.net, is organizing the EVICR.net 18th Members Meeting on October 19-20, 2023, in Milan, Italy.

AIBILI will be organising the EAsDEC congress 2023 on June 1-3, 2023 in Coimbra Portugal.

Do not miss the opportunity to joint a forum of ophthalmologists and diabetologists aimed at increasing the understanding of diabetic retinopathy, its development, diagnosis and treatment.

For more information and registration please visit: https://www.easdec.org/pages/default.asp?id=2

AIBILI has been recognised as an EATRIS Expert Centre covering areas as regulatory strategy and execution and health technology assessment.

EATRIS put out a call for an expression of interest from institutions to provide EATRIS decentralised expert services. Seven applied and were ratified by the EATRIS Boards. The Centres cover a wide range of areas, such as innovation management, regulatory strategy and execution, and health technology assessment.

AIBILI 2022 report is now available!

Please check it here.

Proud to have Patrícia Barreto from AIBILI AMD Research Group receiving the Plácido Prize by the Sociedade Portuguesa de Oftalmologia, during the 65th Portuguese Congress of Ophthalmology.

 

The work entitled “Genetics and the Mediterranean diet: What is the risk for Age-Related Macular Degeneration” was developed by Patrícia Barreto. The assessment of each individual’s genetic risk may be relevant to assess the benefit of personalized non-pharmacological strategies, namely modifiable risk factors for the prevention of Age-Related Macular Disease.

 

Co-workers: Patrícia Barreto, Cláudia Farinha, Rita Coimbra, Maria Luz Cachulo, Joana Barbosa de Melo, Carel Hoyng, Yara Lechanteur, José Cunha-Vaz and Rufino Silva.

To celebrate the 30 years of INFARMED and for the first time in Portugal the National Pharmacovigilance Day, INFARMED organises on 13/12/2022 a session in Lisbon.

AIBILI is one of the Regional Pharmacovigilance Units and its Coordinator, Dr. Lisete Lemos will have a talk dedicated to the challenges and opportunities for the Regional Units.

For more information please check here.

 

Nesta edição do boletim “FARMACOVIGILÂNCIA: Atualizações de segurança de medicamentos” informa-se acerca de novas recomendações no tratamento da síndrome hepatorrenal com medicamentos que contêm terlipressina, recomendações sobre medidas de minimização do risco de reações adversas graves para os medicamentos da classe de inibidores das JAK utilizados em doenças inflamatórias, bem como informação sobre a revisão do perfil de segurança do Topamax® (topiramato) no seguimento de um estudo que revelou risco aumentado de deficiências no neurodesenvolvimento em crianças com exposição pré-natal, e ainda um alerta sobre o uso de vacinas vivas em lactentes cujas mães receberam ustecinumab durante a gravidez. Destacam-se ainda atualizações de segurança sobre as vacinas e medicamentos aprovados para a COVID-19. Por último, é apresentada a atividade científica da Unidade de Farmacovigilância de Coimbra (UFC) e os resultados da sua atividade no terceiro trimestre de 2022.

Consulte: Farmacovigilância – Atualizações de segurança de medicamentos, Vol. 9, n.º 1

Diabetes is a health condition that can affect many parts of the body, including the eyes. Routine eye exams can help identify the early stages of eye problems and protect a person’s vision.

Do not miss AIBILI’s speakers at the roundtables on Personalised Medicine (Inês Pereira Marques) and Big Data/Artificial Intelligence (Luis Mendes).

This Friday, September 16th during the Technology Exhibition dedicated to Health Innovation organised by the Coimbra University and AIBILI.

More information here: https://www.uc.pt/ucbusiness/inovacao-em-saude/

AIBILI has been recognized as a Technology and Innovation Center.
The Technology and Innovation Centers (CTI) are entities dedicated to the production, dissemination and transmission of knowledge, oriented to companies and the creation of economic value, contributing, to the pursuit of public policy objectives, framed in the areas of national priority expertise or regions in which they operate.
ANI was responsible for this process that falls under the Recovery and Resilience Program (PRR).
More information: https://files.dre.pt/2s/2022/08/152000002/0000200003.pdf

The Honorary President of AIBILI, Prof. José Cunha-Vaz, was distinguished today, June 9^th, in Berlin, Germany, with the Arnall Patz Medal. The Arnall Patz Medal is intended to distinguish outstanding contributions to the study of Retinal Vascular Diseases. The ceremony took place during the 45th Congress of the Macula Society.

This distinction is recognition of the scientific career and clinical research activity of José Cunha-Vaz, evident in his innovative contributions, which over the years have greatly contributed to the knowledge and treatment of retinal diseases, and more particularly diabetic retinopathy, a leading cause of blindness.

AIBILI is happy to participate in the Azores Health Summit which will take place on 12-13/05/2022. Our President, Prof. Conceição Lobo, will share AIBILI’s experience in the development and implementation of diabetic retinopathy screening programmes using artificial intelligence. This participation will be complemented by João Diogo Ramos from our partnering company Retmarker SA.

We are honoured to see our recent US Patent published representing another major milestone in AIBILI’s history. This patent US 11,2354,591 B2 follows the EU Patent EP3289565A1 that was received in August 2020.

The team lead by the inventors José Cunha-Vaz and Torcato Santos have developed a method and device that detects and quantifies abnormal increases of retinal extra cellular space using sites of low optical reflectivity from optical coherence tomography (OCT).

This non-invasive method detects changes in the blood-retinal barrier enabling timely treatment and therapy validation in the early stages of diabetic retinopathy.

Do not miss the opportunity to hear about AIBILI Data Centre and its relevance for clinical research development.

Carlos Domingues, AIBILI DataCentre Director will participate in this conference taking place on May 19, 2022, in Porto, Portugal.

This AIBILI infrastructure is the unique DataCentre in the Peninsula Iberia certified by ECRIN.

AIBILI has participated through his Projects and Tech Transfer Manager, Daniel Sanches Fernandes, in the EATRIS PORTUGAL Hub Meeting on April 27, 2022 at INFARMED, I.P. in Lisbon.